Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 132 for:    Methylation Sciences
Previous Study | Return to List | Next Study

Add-On Study of MSI-195 (S-Adenosyl-L-Methionine, SAMe) for Patients With Major Depressive Disorder (MDD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01912196
Recruitment Status : Completed
First Posted : July 31, 2013
Last Update Posted : March 18, 2016
Sponsor:
Information provided by (Responsible Party):
MSI Methylation Sciences, Inc.

Tracking Information
First Submitted Date  ICMJE July 26, 2013
First Posted Date  ICMJE July 31, 2013
Last Update Posted Date March 18, 2016
Study Start Date  ICMJE October 2013
Actual Primary Completion Date September 2015   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: July 30, 2013)
Change in the total Hamilton Depression Rating Scale (HAM-D17) between randomization and end of study. [ Time Frame: assessed from baseline to week 8 (end of study) ]
Based on historical data, the standard deviation is assumed to range between 9 and 12. With a standard effect size of 0.367 a total of at least 120 evaluable patients per group are needed to provide 80% power with a two-sided 5% significance level. HAM-D17 will be derived from the Combined HAM-D28-MADRS Instrument.
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: July 30, 2013)
  • change in the total score of the Montgomery-Asberg Depression Rating Scale (MADRS) [ Time Frame: collected at baseline, weeks 2, 4, 6, 7 and 8 (end of study) ]
    for the MADRS, the number and proportion of patients who are responders at the end of the study and the number and proportion of patients who are in remission at the end of the study will be summarized by treatment group, along with the difference and 95% confidence interval for the difference (based on the Wilson Score method).
  • change in total score of the Clinical Global Impression Improvement Scale (CGI-S) [ Time Frame: assessed from baseline, weeks 2, 4, 7 and 8 (end of study) ]
    the number and proportion of patients who are responders at the end of the study and the number and proportion of patients who are in remission at the end of the study will be summarized by treatment group, along with the difference and 95% confidence interval for the difference (based on the Wilson Score method). Remission is defined as a score of 1 or 2.
  • change from randomization to each study visit in the total score of the Inventory of Depressive Symptomatology-Self Rated (IDS-SR30) [ Time Frame: assessed on baseline visit, Week 2, 4, 6, and 8 (end of study). ]
    A response is defined as a reduction in the IDS-SR30 score of ≥50% and remission is defined as a score of ≤14.
  • Adverse events [ Time Frame: collected at baseline, weeks 1, 2, 3, 4, 6, 8 and 9 (follow up) ]
    collected from signing informed consent through 7 days after the last dose of study treatment. Ascertained by qualified clinician.
  • Columbia Suicide Severity Rating Scale (C-SSRS) [ Time Frame: assessed at baseline, weeks 2, 4, 6 and 8 (end of study) ]
    administered by qualified clinician
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Add-On Study of MSI-195 (S-Adenosyl-L-Methionine, SAMe) for Patients With Major Depressive Disorder (MDD)
Official Title  ICMJE A Double-Blind, Placebo-Controlled, Randomized Add-On Study of MSI-195 (Methylation Sciences Inc. S-Adenosyl-L-Methionine, SAMe) For Patients With Major Depressive Disorder(MDD) Who Have Had An Inadequate Response to Current Antidepressant Therapy
Brief Summary The purpose of this study is to determine the efficacy and safety of 800 mg MSI-195 in reducing symptoms of depression in Major Depressive Disorder (MDD)patients with inadequate response to current antidepressant therapy.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Major Depressive Disorder (MDD)
Intervention  ICMJE
  • Drug: MSI-195
  • Drug: Placebo
Study Arms  ICMJE
  • Experimental: MSI-195

    Patients randomized to the MSI-195 arm will receive treatment with 2 tablets (800 mg) of MSI-195 plus on-going antidepressant therapy (ADT).

    MSI-195 800 mg (two tablets) taken orally once a day in the morning on an empty stomach with water (food should be avoided for at least 1 hr after taking the study drug)

    Intervention: Drug: MSI-195
  • Placebo Comparator: Placebo

    Patients randomized to the placebo arm will receive 2 tablets placebo plus on-going antidepressant therapy (ADT).

    Placebo (two tablets) taken orally once a day in the morning on an empty stomach with water (food should be avoided for at least 1 hr after taking the study drug).

    Intervention: Drug: Placebo
Publications * Targum SD, Cameron BR, Ferreira L, MacDonald ID. An augmentation study of MSI-195 (S-adenosylmethionine) in Major Depressive Disorder. J Psychiatr Res. 2018 Dec;107:86-96. doi: 10.1016/j.jpsychires.2018.10.010. Epub 2018 Oct 18.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: March 17, 2016)
376
Original Estimated Enrollment  ICMJE
 (submitted: July 30, 2013)
286
Actual Study Completion Date  ICMJE September 2015
Actual Primary Completion Date September 2015   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Meets the Diagnostic and Statistical Manual of Mental Disorder, 4th Edition, Text Revision (DSM-IV-TR) criteria for Major Depressive Disorder (MDD)
  • A total score of 16 or higher on the Hamilton Rating Scale for Depression- 17 item version (HAM-D17) at the Screening and Baseline Visits, with a score of ≥2 on mood item 1.
  • Have experienced 1-4 prior Major Depressive Episodes. Patients with more than 5 lifetime episodes (including current episode) will require discussion with the medical monitor prior to inclusion.
  • Failed 1-3 treatment regimens in the current depressive episode
  • Received an adequate dose and duration of Antidepressant Therapy (ADT) (on ADT for at least 6 weeks with a stable dose for at least 3 weeks)

Exclusion Criteria:

  • Failed 4 or more adequate treatment regimens in current episode of depression
  • patient may have a significant risk for suicidal behavior during the course of their participation in the study
  • Intolerance to SAMe; Prior use of MSI-195
  • History of any of the following psychiatric disorders: eating disorder within 6 months; obsessive compulsive disorder, psychotic disorder, bipolar disorder, mental retardation, dementia or other forms of cognitive impairment at any time or alcohol or substance abuse
  • >3X upper limit of normal (ULN) Alkaline Phosphatase, aspartate aminotransferase (AST), alanine aminotransferase (ALT); >1.5X ULN total bilirubin
  • Pregnant or lactating women
  • Any history of seizures, excluding febrile seizures
  • Known positivity for human immunodeficiency virus
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 21 Years to 70 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01912196
Other Study ID Numbers  ICMJE MSI-CP.002
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party MSI Methylation Sciences, Inc.
Study Sponsor  ICMJE MSI Methylation Sciences, Inc.
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account MSI Methylation Sciences, Inc.
Verification Date March 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP